We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Equivalency Remains Key Issue in Biologics Patents Realm
Equivalency Remains Key Issue in Biologics Patents Realm
August 23, 2005
Case law provides only inexact guidelines on just how much a protein sequence must vary in order to get around the patent on a biological therapy, according to a life sciences patent attorney.